Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ReCyte Therapeutics
Alameda, California, United Statesrecyte.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ReCyte Therapeutics has demonstrated successful isolation of novel pericyte-like progenitor cells from human embryonic stem cells. These cells show promise in preclinical models for restoring blood flow in ischemic diseases, and the company has also developed an angiogenesis drug screening assay; no clinical-stage data reported to date.
- Therapeutic areas
- Cardiovascular
- Modalities
- Induced pluripotent stem cell derived therapyEmbryonic stem cell derived therapyCell therapy
- Industry
- Biotech
02
Partnerships
Ascendance Biotechnology (distribution of VascuNet assay)
Beyond the preview
Go deeper on ReCyte Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReCyte Therapeutics.